AstraZeneca Shares Drop After Heart Disease Drug Fails Clinical Trial
Shares of AstraZeneca dropped significantly after its heart disease drug Wainua failed to meet trial goals. The treatment did not outperform a placebo in preventing complications for patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). This unexpected result led to an intraday drop as high as 10.6% on the London market.
Topics: AstraZeneca ATTR-CM drug development Ionis Pharmaceuticals stock market reaction